NOW AVAILABLE

Pheburane® Coated Oral Pellets:

An innovative formulation of sodium phenylbutyrate (NaPB) with a special coating designed to mask the awful taste

An innovative formulation of sodium phenylbutyrate (NaPB) with a special coating designed to mask the awful taste
The safe, effective, and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain Urea Cycle Disorders (UCDs)
  • An alternative to other UCD treatments – no tablets, no syringes, & no mixing required.
  • Measured with a reusable calibrated dosing spoon.
  • Offered at a price that is similar to the other sodium phenylbutyrate (NaPB) products and significantly less expensive than the most commonly prescribed chronic UCD treatment.
  • With Pheburane®, UCD patients found the ease of administration & acceptability much higher when compared to non-taste-masked NAPB products in a Cohort Temporary Utilization Authorization (ATU) Survey of Patients2.
    Please see Clinical Experience for additional study information.

Episodes of acute hyperammonemia may occur in patients while on Pheburane®. Pheburane® is not indicated for the treatment of acute hyperammonia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels. Pheburane® treatment should be supervised by a healthcare provider experienced in the treatment of UCDs.

10 seconds clock

PALATABLE – Special coating designed to mask the awful taste of NaPB.1

PROVEN– Safe & Effective adjunctive therapy1-4

PELLETS– Very small coated oral pellets – no mixing or syringes needed!

PRICE– Offered at a similar cost to other NaPB products.

What is Pheburane®?1

The palatable, safe, and effective treatment option designed to mask the awful taste of sodium phenylbutyrate (NaPB). Pheburane® is indicated as adjunctive therapy to the standard of care, which includes dietary management, in the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS).

Pheburane® is not indicated for the treatment of acute hyperammonemia.

Do your patients complain about the awful taste of their current sodium phenylbutyrate (NaPB)?

Do they have difficulties taking it?

It is very important that UCD patients adhere to their diet and prescription treatment as failure to do so may lead to life-threatening complications.

PHEBURANE®PELLETS: A polymer coating designed to mask the awful taste of NaPB

P=PALATABLE

P=PELLETS

Pheburane®coated pellets are small and round with sugar cores, a layer of NaPB – the active ingredient, and a coating of ethyl cellulose, a well-known taste-masking agent.5Learn more
Pheburane Coating

Impact of Urea Cycle Disorders4,5

Urea Cycle Disorders (UCDs) are a group of rare inherited metabolic diseases characterized by deficiencies of one of the enzymes and transporters involved in the urea cycle. The urea cycle is necessary for the removal of nitrogen produced from the breakdown of protein. UCDs are characterized by hyperammonemia and life-threatening hyperammonemic crises.5

Increasing blood ammonia levels can lead to complications throughout the body, including symptoms like:

In Severe Cases, Even Death
Pharmacological treatment of UCDs involves alternative ammonia-scavenging drugs, one of which is sodium phenylbutyrate (NaPB). NaPB has a notoriously awful taste and odor which can lead to taste aversion.5

In UCDs, if patients fail to comply with their NaPB treatment, it may result in symptoms of poor control of plasma ammonia levels that may lead to potentially irreversible and life-threatening situations.4

A taste-masked formulation may improve compliance and adherence to treatment which is critical to the efficacy of NaPB treatment in UCD patients.4

PHEBURANE®P=PROVEN

Study Title: Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) Survey of Patients in France Treated with Pheburane® (sodium phenylbutyrate) Taste-Masked Granules2†

Study Design2* Inclusion of patients in the cohort temporary utilization authorization (ATU) protocol required the diagnosis and treatment of UCD by one of the national reference centers of inherited metabolic diseases. If admitted, subjects could be switched from non-taste-masked NaPB to Pheburane®. 25 patients were admitted into the study, all indicating the unacceptability of their previous non-taste-masked NaPB treatment with a 1-year treatment period.

NO hyperammonemic episodes were experienced in the Pheburane® study treatment group (n=10).

Pheburane® treatment led to significantly lower plasma ammonia (NH3) and glutamine (Gln) values compared to non-taste-masked NaPB treatments.

* Based on temporary utilization authorization (ATU) protocol in France to analyze safety and efficacy in the treated cohort of patients with UCD.

† The FDA-approved term pellets is used to describe Pheburane® in the United States. The term granules is used to describe Pheburane® in other countries.

 

The most common adverse reactions to Pheburane® (incidence ≥ 3%) are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion.

Clinical Study Info

How to Take Pheburane®1,5

Dietary restriction of protein combined with an ammonia-scavenging treatment is one of the main therapeutic modalities used in the chronic treatment of UCDs. NaPB has been the standard treatment of UCDs for over 25 years.

Pheburane® is an innovative taste-masked formulation of NaPB, indicated as adjunctive therapy to the standard of care which includes dietary management for the treatment of certain UCDs

 

2 Ways Pheburane® can be taken with food consumption (meal or snack):

  • swallowed with a beverage – e.g., water, fruit juices, protein-free infant formulas
  • sprinkled on soft food – apple sauce or carrot puree* – immediately before eating

* Administration of Pheburane® oral pellets with other foods has not been studied and is not recommended. Additionally, administration with soft food is only recommended in patients old enough to consume soft foods.

 

Patients should swallow pellets immediately (within 10 seconds) to minimize dissolution of coating. Please see Instructions for Use.

10 seconds clock

10 SecondWindow of Opportunity

The in vitro test profile of Pheburane® coated pellets indicates that the NaPB was only released after approximately 10 seconds followed by a slow release over several minutes. Therefore, patients must take as directed and optimally within 10 seconds to avoid any bad taste.4

PHEBURANE®P=PRICE

Medunik USA offers Pheburane® through its UNIK Support Program – designed to support each unique patient. Unik Support (pronounced yoo·neek) has specialized services for Prescribers and Patients, including a Savings Program.

Medunik USA provides Pheburane® and all its added benefits at a cost that is similar to the other NaPB products and significantly less expensive than the most commonly prescribed chronic UCD treatment.

Important Safety Information

INDICATION

Pheburane® is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS).

 

Limitations of Use

Episodes of acute hyperammonemia may occur in patients while on Pheburane®. Pheburane® is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels.

WARNINGS AND PRECAUTIONS

 

Neurotoxicity of Phenylacetate

Increased exposure to phenylacetate, the major metabolite of Pheburane®, may be associated with neurotoxicity in patients with UCDs. If symptoms of vomiting, nausea, headache, somnolence or confusion are present in the absence of high ammonia levels, consider reducing the dose of Pheburane®.

 

Hypokalemia

Renal excretion of phenylacetylglutamine may induce urinary loss of potassium. Monitor serum potassium during therapy, and initiate appropriate treatment when necessary.

 

Conditions Associated with Edema

In order to decide if administration of Pheburane® is appropriate in patients with diseases that involve edema, calculate the total amount of sodium patients will be exposed to, based on their weight or body surface area.

 

If a patient develops new-onset edema or worsening edema while on treatment, discontinue administration of Pheburane® and initiate appropriate therapy.

 

Diabetes Mellitus, Hereditary Fructose Intolerance, Glucose-Galactose Malabsorption or Sucrase-Isomaltase Insufficiency

Avoid use of Pheburane® in patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency.

ADVERSE REACTIONS

The most common adverse reactions (incidence > 3%) are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion.

DRUG INTERACTIONS

  • Valproic acid, Haloperidol, or Corticosteroids: May increase plasma ammonia levels. Monitor ammonia levels closely.
  • Probenicid: May inhibit renal excretion of metabolites of Pheburane® including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity.

OVERDOSAGE

Overdoses of Pheburane® exceeding ten-fold the maximum recommended dosage may produce emesis, CNS depression, metabolic acidosis with or without respiratory alkalosis, hypernatremia, hypokalemia, and hypophosphatemia. Symptoms of overdose overlap with those of acute hyperammonemia. If overdose occurs, discontinue Pheburane®, monitor plasma phenylacetate and ammonia levels closely, and institute appropriate emergency management.

To report suspected adverse reactions, contact Medunik USA at 1-844-884-5520 or medicalinfo@medunikusa.com.

Please read the Full Prescribing Information.

References:

  1. Pheburane® (sodium phenylbutyrate) oral pellets [Prescribing Information]. Medunik USA, Inc.
  2. Kibleur Y, Dobbelaere D, Barth M, Brassier A, Guffon N. Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in france treated with Pheburane® (Sodium Phenylbutyrate) taste-masked granules. Paediatr Drugs. 2014.
  3. Kibleur Y, Guffon N. Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules. Paediatr Drugs. 2016 Apr;18(2):139-44. doi: 10.1007/s40272-015-0159-8. PMID: 26747635.
  4. Guffon N, Kibleur Y, Copalu W, Tissen C, Breitkreutz J. Developing a new formulation of sodium phenylbutyrate. Arch Dis Child. 2012 Dec;97(12):1081-5. doi: 10.1136/archdischild-2012-302398. Epub 2012 Aug 31. PMID: 22941860.
  5. Peña-Quintana L, Llarena M, Reyes-Suárez D, Aldámiz-Echevarria L. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. Patient Prefer Adherence. 2017 Sep 6;11:1489-1496. doi: 10.2147/PPA.S136754. PMID: 28919721; PMCID: PMC5593420.